[1]

Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, et al. 2017. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. New England Journal of Medicine 376(15):1419−1429

doi: 10.1056/nejmoa1610187
[2]

Lawrence JM, Divers J, Isom S, Saydah S, Imperatore G, et al. 2021. Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017. JAMA 326(8):717

doi: 10.1001/jama.2021.11165
[3]

Lim LL, Jones S, Cikomola JC, Hivert MF, Misra S. 2025. Understanding the drivers and consequences of early-onset type 2 diabetes. The Lancet 405(10497):2327−2340

doi: 10.1016/S0140-6736(25)01012-8
[4]

Gregg EW, Hora I, Benoit SR. 2019. Resurgence in diabetes-related complications. JAMA 321(19):1867−1868

doi: 10.1001/jama.2019.3471
[5]

Salama M, Balagopal B, Fennoy I, Kumar S. 2023. Childhood obesity, diabetes, and cardiovascular disease risk. The Journal of Clinical Endocrinology & Metabolism 108(12):3051−3066

doi: 10.1210/clinem/dgad361
[6]

Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, et al. 2022. Long-term complications in youth-onset type 2 diabetes. Yearbook of Paediatric Endocrinology 385(5):416−426

doi: 10.1530/ey.19.12.3
[7]

Zhang K, Kan C, Han F, Zhang J, Ding C, et al. 2023. Global, regional, and national epidemiology of diabetes in children from 1990 to 2019. JAMA Pediatrics 177(8):837

doi: 10.1001/jamapediatrics.2023.2029
[8]

Kan C, Zhang K, Han F, Hou N, Sun X. 2025. Updated insights on childhood diabetes epidemiology 2019-2021 and projections to 2045. JAMA Pediatrics 179(2):205

doi: 10.1001/jamapediatrics.2024.5105
[9]

Magge SN, Wolf RM, Pyle L, Brown EA, Benavides VC, et al. 2022. The coronavirus disease 2019 pandemic is associated with a substantial rise in frequency and severity of presentation of youth-onset type 2 diabetes. The Journal of Pediatrics 251:51−59. e2

doi: 10.1016/j.jpeds.2022.08.010
[10]

Rahmati M, Yon DK, Lee SW, Udeh R, McEvoy M, et al. 2023. New-onset type 1 diabetes in children and adolescents as postacute sequelae of SARS-CoV-2 infection: a systematic review and meta-analysis of cohort studies. Journal of Medical Virology 95(6):e28833

doi: 10.1002/jmv.28833
[11]

Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen EA, et al. 2022. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years - United States, March 1, 2020-June 28, 2021. MMWR Morbidity and Mortality Weekly Report 71(2):59−65

doi: 10.15585/mmwr.mm7102e2
[12]

Patterson CC, Harjutsalo V, Rosenbauer J, Neu A, Cinek O, et al. 2019. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25year period 1989–2013: a multicentre prospective registration study. Diabetologia 62(3):408−417

doi: 10.1007/s00125-018-4763-3
[13]

Kamrath C, Rosenbauer J, Eckert AJ, Siedler K, Bartelt H, et al. 2022. Incidence of type 1 diabetes in children and adolescents during the COVID-19 pandemic in Germany: results from the DPV registry. Diabetes Care 45(8):1762−1771

doi: 10.2337/dc21-0969
[14]

GBD 2023 Causes of Death Collaborators. 2025. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet 406:1811−1872

doi: 10.1016/S0140-6736(25)01917-8
[15]

GBD 2023 Disease and Injury and Risk Factor Collaborators. 2025. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet 406:1873−1922

doi: 10.1016/S0140-6736(25)01637-X
[16]

GBD 2015 Healthcare Access and Quality Collaborators. 2017. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. The Lancet 390:231−266

doi: 10.1016/s0140-6736(17)30818-8
[17]

Ordunez P, Martinez R, Soliz P, Giraldo G, Mujica OJ, et al. 2019. Rheumatic heart disease burden, trends, and inequalities in the Americas, 1990–2017: a population-based study. The Lancet Global Health 7(10):e1388−e1397

doi: 10.1016/S2214-109X(19)30360-2
[18]

Hankey BF, Ries LA, Kosary CL, Feuer EJ, Merrill RM, et al. 2000. Partitioning linear trends in age-adjusted rates. Cancer Causes & Control 11(1):31−35

doi: 10.1023/A:1008953201688
[19]

Pan Y, Liu Q, Zhang N, Peng S, Li X, et al. 2025. Global assessment of leukemia care quality: insights from the quality of care index (QCI) from 1990 to 2021. eClinicalMedicine 79:102996

doi: 10.1016/j.eclinm.2024.102996
[20]

Liang D, Wang L, Zhong P, Lin J, Chen L, et al. 2025. Perspective: global burden of iodine deficiency: insights and projections to 2050 using XGBoost and SHAP. Advances in Nutrition 16(3):100384

doi: 10.1016/j.advnut.2025.100384
[21]

Liang D, Wang L, Liu S, Li S, Zhou X, et al. 2024. Global incidence of diarrheal diseases—an update using an interpretable predictive model based on XGBoost and SHAP: a systematic analysis. Nutrients 16(18):3217

doi: 10.3390/nu16183217
[22]

Liu Z, Xu K, Jiang Y, Cai N, Fan J, et al. 2021. Global trend of aetiology-based primary liver cancer incidence from 1990 to 2030: a modelling study. International Journal of Epidemiology 50(1):128−142

doi: 10.1093/ije/dyaa196
[23]

Broyles ST, Denstel KD, Church TS, Chaput JP, Fogelholm M, et al. 2015. The epidemiological transition and the global childhood obesity epidemic. International Journal of Obesity Supplements 5(2):S3−S8

doi: 10.1038/ijosup.2015.12
[24]

Guvenc F, Danska JS. 2025. The intestinal microbiome in type 1 diabetes: bridging early childhood exposures with translational advances. Current Opinion in Immunology 94:102553

doi: 10.1016/j.coi.2025.102553
[25]

Keskesiadou GN, Tsokkou S, Konstantinidis I, Georgaki MN, Sioga A, et al. 2024. Endocrine-disrupting chemicals and the development of diabetes mellitus type 1: a 5-year systematic review. International Journal of Molecular Sciences 25(18):10111

doi: 10.3390/ijms251810111
[26]

Lugar M, Eugster A, Achenbach P, von dem Berge T, Berner R, et al. 2023. SARS-CoV-2 infection and development of islet autoimmunity in early childhood. JAMA 330(12):1151−1160

doi: 10.1001/jama.2023.16348
[27]

Hemat Jouy S, Tonchev H, Mostafa SM, Mahmoud AM. 2025. Post-COVID metabolic fallout: a growing threat of new-onset and exacerbated diabetes. Biomedicines 13(6):1482

doi: 10.3390/biomedicines13061482
[28]

Cavanagh A, Adhikary S, Denny S. 2025. Psychosocial well-being of adolescents and young adults living with chronic illness. Internal Medicine Journal 55(11):1814−1823

doi: 10.1111/imj.70198
[29]

Zhao X, Jiang L, Sun W, Tang S, Kang X, et al. 2025. Understanding the interplay between COVID-19 and diabetes: insights for the post-pandemic era. Frontiers in Endocrinology 16:1599969

doi: 10.3389/fendo.2025.1599969
[30]

Singh AK, Khunti K. 2022. COVID-19 and diabetes. Annual Review of Medicine 73:129−147

doi: 10.1146/annurev-med-042220-011857
[31]

Wu Z, Wang J, Ullah R, Chen M, Huang K, et al. 2024. Covid 19 and diabetes in children: advances and strategies. Diabetology & Metabolic Syndrome 16(1):28

doi: 10.1186/s13098-024-01267-2
[32]

Price AM, Maayan T, Wake MA, Hiscock H. 2014. Is glycosylated haemoglobin associated with psychosocial stress in non-diabetic 6-year-olds? Journal of Paediatrics and Child Health 50(2):153−157

doi: 10.1111/jpc.12415
[33]

Rewers M. 2025. Health economic considerations of screening for early type 1 diabetes. Diabetes, Obesity and Metabolism 27(S6):69−77

doi: 10.1111/dom.16522
[34]

Castellanos L, Tuffaha M, Koren D, Levitsky LL. 2020. Management of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus. Pediatric Drugs 22(4):357−367

doi: 10.1007/s40272-020-00397-0
[35]

Ohman-Hanson R, Alonso GT, Pyle L, McDonough R, Clements M. 2024. Management of diabetic ketoacidosis in children: Does early insulin glargine help improve outcomes? Journal of Diabetes 16(8):e13597

doi: 10.1111/1753-0407.13597
[36]

Henry Z, Villar Fimbel S, Bendelac N, Perge K, Thivolet C. 2024. Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics. Diabetes, Obesity and Metabolism 26(2):557−566

doi: 10.1111/dom.15344
[37]

Holt RIG, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, et al. 2021. The management of type 1 diabetes in adults. a consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 44(11):2589−2625

doi: 10.2337/dci21-0043
[38]

Schiel R, Voigt U, Ross I, Braun A, Rillig A, et al. 2006. Structured diabetes therapy and education improves the outcome of patients with insulin treated diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes 114(1):18−27

doi: 10.1055/s-2005-873079